



New Titles: Cancer Research

Titles published by Nova Science


Cancer Etiology,
Diagnosis &
Treatments

Horizons In Cancer
Research

Medicine & Biology
Research
Developments

Nutrition & Diet
Research Progress

Radiation
Oncology: Clinical,
Translational &
Laboratory
Research



National Cancer Research Institute Cancer Conference 2019


3-5th November 2019

Scottish Event Campus, Glasgow

Contents

Cancer Etiology, Diagnosis & Treatments Series	1
Horizons In Cancer Research Series	10
Medicine & Biology Research Developments Series	10
Nutrition & Diet Research Progress	11
Radiation Oncology: Clinical, Translational & Laboratory Research Series	11

Cancer Etiology, Diagnosis & Treatments Series




Encyclopedia of Breast Cancer New Research - 3 Volume Set

Edited by Gabriel Adams, Edna Dunn

This 3-volume set covers a wide range of topics, including:

- gemcitabine
- oophorectomies
- breast cancer growth inhibition
- exosomes
- tumor infiltrating lymphocytes (Imprint: Nova Medicine and Health)

HB 9781536156973 £471.99 July 2019 Nova Science Publishers 765 pages




Bladder Cancer Research Advances and Clinical Challenges

Edited by Ja Hyeon Ku

Bladder cancer is the fifth most common cancer with an estimated 60,490 new cases and 12,240 deaths expected for 2017 in the US alone. The diagnosis and treatment of bladder cancer in the current era is in the midst of a revolution. Recent research has focused on the evaluation of genetic markers to provide diagnostic and prognostic information in bladder cancer. In recent years, systemic therapies using a variety of immunotherapeutic strategies have evolved for the treatment of urothelial carcinoma.

Bladder Cancer: Research Advances and Clinical Challenges is a textbook on bladder cancer written by leading world experts in the field. This new book presents the latest research in this field. It has ten chapters that discuss a wide variety of the most important topics, including: cancer stem cells; molecular biomarkers; cancer detection and monitoring; clinical prognostication; immune checkpoint inhibitors; etc. It will equally be appreciated by urologists as well as scientists. The editor hopes that this book will offer the most contemporary and useful information for specialists involved in bladder cancer.

HB 9781536133547 £185.99 April 2018 Nova Science Publishers 249 pages




Acute Myeloid Leukaemia (AML) **Symptoms, Diagnosis and Treatment** Edited by Irvin Mendez

Acute myeloid leukemia is the most common adult acute leukemia, but its etiology in individual patients is poorly understood. An increased risk of acute myeloid leukemia may be inherited (through congenital hematologic diseases and syndromes or germline disorders) or be acquired due to a lifetime of exposure to environmental or chemical agents, or genotoxic stress. In this collection, the authors explore risk factors for acute myeloid leukemia, newer epidemiologic studies on the connections between these risks and clinical phenotypes and outcomes of the disease.

The subsequent chapter evaluates different prognostic factors and stratifications of risk that have been published in an attempt to assess the influence of acute myeloid leukemia progression on the overall survival of myelodysplastic syndromes patients, evaluating them in a population-based registry.

Many acute myeloid leukemia patients cannot tolerate standard chemotherapy due to its high toxicity. A milder therapy for acute myeloid leukemia has long been sought after, and until now the only successful clinical application has been all-trans-retinoic acid-based therapy for just one subtype of acute myeloid leukemia, acute promyelocytic leukaemia. The concluding chapter aims to address other therapeutic candidates.

PB 9781536143454 £78.99 October 2018 Nova Science Publishers 111 pages




Adjuvant Chemotherapy **Current Practices, Efficacy and Future Directions** Edited by Yasushi Tsuji

In the age of constant knowledge via computer accessibility, the effort to write a book on adjuvant chemotherapy may seem almost futile. However, the information seen online is usually fragmented, without context, and often somewhat unreliable. This book aims to provide a handy and reliable reference to better understand both the current situation and the future directions in the field of adjuvant chemotherapy. Its ten chapters covering major cancers were written by prominent researchers with decades of experience in clinical settings as well as in related fields of research.

Owing mostly to the development of novel cancer drugs, cytotoxic agents, targeting agents and immune check point inhibitors, the prognosis of all cancers has markedly improved. On the other hand, determining the best way to use these drugs is becoming more and more complicated, and most patients after recurrence are still unlikely to be cured. Carefully planned and meticulously executed surgery, appropriate adjuvant chemotherapy and radiotherapy still play major roles in treatment, and they can significantly increase cure rates, especially in the advanced stages. This book contains a wealth of the latest international data and detailed information assist professionals in making the best possible decisions regarding specific and patient-oriented treatments.

From the general introduction to the principles of adjuvant chemotherapy in chapter one to all the details in the chapters covering specific cancers, we hope this book will inspire veterans in the field with new ideas and help to guide and educate young doctors and researchers, all towards the ultimate goal of providing better care for our patients.

HB 9781536139334 £219.99 September 2018 Nova Science Publishers 296 pages



**On Display with
Wisepress**

The Story of Hydra Portrait of Cancer as a Stem-Cell Disease

Shi-Ming Tu

The questions we ask in this book about cancer are actually quite elementary. What is the origin of cancer? Does cancer arise in any cell in the body, or only in certain cells? Is cancer a genetic or a stem-cell disease?

We illustrate that cancer is a multicellular rather than a unicellular process, a cellular rather than a genetic problem, and a stem-cell rather than a somatic-cell disease. We reveal that the incredible resemblance between a cancer cell and a stem cell suggests that they are intimately related. The uncanny ingenuity of a cancer cell is also innate in a stem cell.

The recognition that cancer has a stem-cell origin indicates that a stem-cell theory of cancer may be the unified theory that we need to make sense of the torrents of new data and new insights into different facets of cancer, to see how they fit together into one picture, and to disarm the disease. A stem-cell theory of cancer can potentially accept, embrace, and integrate all of its genetic, epigenetic, proteomic, and metabolic aspects.

Such a unified theory can account for all cancer hallmarks, including metastasis, heterogeneity, dormancy, and immune evasion. It predicts that multimodal therapy may be more beneficial than targeted therapy, and integrated medicine more effective than precision medicine for the management of all but the simplest tumors. It predicts that when we have the correct cancer theory, clinical progress will advance by monumental leaps rather than incremental steps. Indeed, I predict that successful clinical outcomes will ultimately provide irrefutable validation that cancer is a stem-cell disease.

Therefore, the thesis of this book is actually quite simple. When we have a pertinent and correct theory of the origin of cancer, all ideas, observations, experiments, and treatments will begin to fall into place and make perfect sense. We would like to convince readers that a stem-cell theory is the elusive, long-sought unified theory, the theory of all theories, of cancer.


HB 9781536153736 £219.99 June 2019 Nova Science Publishers 350 pages

Basal Cell Carcinoma Advances in Research and Treatment

Edited by Michael R. Migden, Leon Chen, Sirunya Silapunt

As a leader in cutaneous oncology and a professor at the MD Anderson Cancer Center, senior editor Dr. Migden assembled a panel of authors with considerable expertise to participate in the writing of this book. Basal Cell Carcinoma: Advances in Research and Treatment provides the most comprehensive overview of evidence-based treatment approaches for the most common cancer worldwide – basal cell carcinoma. The first part of this book details the epidemiology, risk factors, pathophysiology, and different histologic subtypes of basal cell carcinoma highlighted with high-resolution histopathology images. The second part of the book provides an in-depth review of different treatment modalities including topical therapy, local immunotherapy with interferon, cryotherapy, electrodesiccation and curettage, radiotherapy, and surgical approaches with Mohs micrographic surgery, head and neck surgery, and oculoplastic surgery. The final part of the book highlights the utilization of innovative technologies such as photodynamic therapy and lasers for the treatment of basal cell carcinoma while providing excellent cosmetic outcomes, as well as emerging systemic therapeutic options utilizing hedgehog pathway inhibitors and immunotherapy for the difficult-to-treat disease state, advanced basal cell carcinoma. This book will serve as an informative practical guide for physicians, mid-level providers, and trainees for years to come.

HB 9781536153392 £219.99 June 2019 Nova Science Publishers 359 pages



The Medulloblastoma Book

Edited by Dimitris Kombogiorgas


This book offers a unique insight into the “medulloblastoma world,” and provides both a broad review and detailed analysis of this brain tumour. It starts with the history of medulloblastoma as a term, and as a distinct entity in nosology, and then explores in depth, the diagnosis, genetics, neurosurgical, and oncological management of medulloblastoma patients, as well as their outcome and long-term complications. Furthermore, novel therapies and next generation clinical trials in medulloblastoma are discussed. This landmark text is written by leading authorities in the research and treatment of medulloblastoma.

It provides information based on clinical trials, major clinical series, and the authors’ outstanding experience and knowledge. It contains numerous, detailed illustrations, which help the reader understand the new knowledge easily. Also, it includes pitfalls and perils of the management of patients with medulloblastoma.

The Medulloblastoma Book is useful to both medical specialists such as paediatricians, radiologists, neurosurgeons, and oncologists who are looking for the latest research in an integrated text, containing the current knowledge about medulloblastoma. This book is also useful for medical students, nurses, residents, and young researchers who are interested in medulloblastoma, neurosurgery, and neuro-oncology.

This text aims to enrich medical literature throughout the world by providing an integrated understanding of medulloblastoma in a comprehensive and practical manner, by being written by scientists working at the cutting-edge of their specialities.

HB 9781536151527 £219.99 May 2019 Nova Science Publishers 350 pages



New Developments in Oncology Research

Edited by Marcos T. Blair


In the opening chapter, authors discuss the current literature that describes the application of Palliative Medicine services in advanced cancer, models of Palliative Care delivery by site and mode of practice, cost-effectiveness of early Palliative Medicine referral patterns and national and international Palliative Medicine practice and referral guidelines. The chapter will also discuss the outcomes of Palliative Medicine in Oncology focusing on the improvements in patient clinical and quality of life outcomes.

Next, a systematic chapter aims to better explain the mechanisms that underlie electrolyte disturbances in cancer patients, to stress on the serious prognostic implications involved and to provide practical and useful indications for the prompt diagnosis, management and therapy of electrolyte disorders.

The authors discuss over thirty $Pt\{\eta^2-P(X)_n\}Cl_2$ ($n = 5,6,7,8$) derivatives in which organodiphosphines create wide varieties of the metallocyclic rings: eight-membered (PC_5P , PC_2OC_2P , PC_2NC_2P), nine-membered (PC_6P , POC_4OP), ten-membered (POC_5OP , PC_2OCOC_2P , PC_3OC_3P), and eleven-membered (PC_8P , PNC_6NP , POC_6OP). Another included study covers eighty five Pt(II) complexes with an inner coordination sphere of $cis-PtP_2Cl_2$. The P- donor ligands are organodiphosphines which create four- and five-membered metallocyclic rings with the PCP, PNP, PC-CP, PC=CP, PN_2P and PCOP types. In the penultimate chapter, the authors examine over forty $cis-Pt(\eta^2-PXXXX)Cl_2$ derivatives in which organodiphosphines create six-membered metallocyclic rings, and the concluding chapter examines over thirty $cis-Pt(\eta^2-PXXXX)Cl_2$ derivatives in which organodiphosphines create seven-membered metallocyclic rings.

HB 9781536153651 £152.99 May 2019 Nova Science Publishers 167 pages

**On Display with
Wisepress**




Frontiers in Leukemia Pharmacotherapy

Edited by Lunawati L. Bennett

Frontiers in Leukemia Pharmacotherapy provides a comprehensive overview of the various leukemic disorders found in both children and adults, with an emphasis on current and novel treatment approaches for the healthcare practitioner. By focusing on the unique therapeutic challenges of leukemia, this book aims to meet the diverse needs of physicians, pharmacists, nurses, and other healthcare professionals with an interest in serving patients with leukemia.

This comprehensive book is divided into nineteen chapters. Content includes information on specific leukemic disease states in both children and adults. Written by researchers and clinical practitioners, chapters cover a wide array of leukemic topics. Topics include understanding the molecular and genetic basis of acute and chronic leukemia, pharmacology of anti-leukemic agents including traditional chemotherapies, targeted immunotherapy, and tyrosine kinase inhibitors. The epidemiology, etiology, pathogenesis, disease classification, clinical presentation, pathologic features, diagnosis, prognosis, and treatment guidelines for myelodysplastic syndrome, promyelocytic leukemia, pediatric and adult acute and chronic leukemia are other topics covered in more detail. Other topics include: Redox homeostasis occurring in leukemia and the role of antioxidants, supportive care for the leukemic patient experiencing complications from chemotherapy, palliative care for termination of those with leukemia, pharmacometrics using computational modeling to support drug development in leukemia, and future agents that are in clinical trials in our fight against leukemia. Reputable books, journals, monographs, clinical trials, and other resources were used to provide up-to-date medical information useful to assist healthcare professionals in the management of leukemia. *Frontiers in Leukemia Pharmacotherapy* is an excellent resource for curious healthcare professionals involved in the care of leukemic disorders.

HB 9781536149609 £219.99 March 2019 Nova Science Publishers 446 pages



Clinical Oncoproteomics

Proteome-Based Personalized Anti-Cancer Therapy


Andrey S. Bryukhovetskiy

This monograph is dedicated to the issues of clinical oncoproteomics, its role and place in contemporary medicine in general, and in particular, oncology. This book reviews various academic viewpoints on the informational component and value of the data of clinical oncoproteomics for the diagnostics and treatment of malignant tumors using cellular, genomic and post-genomic technologies.

The monograph summarizes modern concepts of carcinogenesis and describes the author's informational theory of cancer onset. The book presents theoretical, methodological and technical aspects of the innovative medical technology of the personalized proteome-based cell therapy of neoplasms. The author describes his own experience in mapping, proteomic and transcriptomic profiling of the postnatal regional progenitors and cancer stem cells of cancer patients, and the methods of bioinformational processing and mathematical modeling of the results. This book also demonstrates mathematical instruments that are used to detect the regulatory targets of the proliferative and reproductive functions of cancer stem cells in tumors and production of the targeted individually tailored anti-cancer proteome-based cell products. The mechanisms, limitations and future of these technologies are examined relying on the evidence of the clinical proteomics.

This book is intended for a broad range of specialists, including clinical doctors of different specializations, such as oncologists, surgeons, neurologists, neurosurgeons, intensivists, immunologists, biochemists, molecular biologists, geneticists, professors and students of medical colleges, as well as specialists working with the issues of cell therapy and personalized medicine.

HB 9781536144772 £219.99 December 2018 Nova Science Publishers 356 pages



Quantum Biology

Methods to Cure Malignant Cancerous Cells into Cells with Reduced CpG Methylation Accessible to Eating Cell Systems

Kohji Hasunuma


The 3O_2 generated by the photolysis process will accept enough energy from triplet-chlorophyll to provide the energy states of a singlet of oxygen (1O_2), $^1\Delta_g$, and $^1\Sigma_g^+$, with emissions in the range of 200 – 500 μm . The 1O_2 would react with unsaturated fatty acids to form malondialdehyde (MDA).

In humans, the methylation of CpG islands in cancerous cells is so high that the sensing ability of the occurrence of environmental changes to genes with CpG islands could be insufficient for genes with CpG islands. House-keeping genes function independently by sensing various types of information from neighboring cells, and supporting the proliferation of cells behaving as cancerous cells so that the cells achieve a malignant, metastatic state. The CpG island-controlled genes (47,000/human haploid genome) and CpG island-independent genes (33,000/human haploid genome) co-regulate in the normal cell systems.

FAD, FMN, riboflavin, and derivatives of heme groups are well known as photosensitizers, which emit 1O_2 with ROS in the solution in vivo. In sunlight, photosensitizers will function as the generators of 1O_2 and ROS. During the daytime, there is a plentiful supply of 1O_2 and ROS from the sunlight, and which inevitably constitutes the circadian rhythms of ROS. The repeated evolution of 1O_2 and ROS would function to stimulate the methylation of CpG islands.

The tubulin structures, extending from the plasma membrane to two centrosomes and located along the sides of the nucleus, are designated as asters. In darkness, the protein complex of NDPK-1/catalase is located in the plasma membrane. However, upon receiving light illumination, the NDPK-1/catalase function captures 1O_2 using catalase. The NDPK-1 binds NADH and supplies electrons to bind 1O_2 that is bound to the catalase, resulting in the release of a super oxide (O_2^-). The NDPK/catalase protein complex located in the plasma membrane moves along the aster-forming tubulin structure to the cytosol. As a result, the nucleus is protected from 1O_2 by the wall, which is composed of the NDPK-1/catalase complex.

PB 9781536147759 £78.99 February 2019 Nova Science Publishers 63 pages



The Sentinel Lymph Node

Detection, Procedures and Clinical Implications


Edited by Ambrogio Pietro Londero, Serena Bertozzi, Carla Cedolini

The Sentinel Lymph Node: Detection, Procedures and Clinical Implications gathers an overview of the sentinel lymph node biopsy procedure among different surgical settings (i.e., melanoma, breast, thyroid, vulva, endometrium, cervix, colon, anus, liver, gastric, urological and ovarian cancers). This book consists of eighteen chapters; the rationale and the purpose of this technique, which allows adequate lymph node staging while sparing patients from unnecessary complete lymph node dissections and the traditional harmful complications associated with them are discussed.

Furthermore, this book outlines the technical aspects of the procedure (which are also accurately covered) from the various intraoperative sentinel node detection techniques to the subsequent sentinel lymph node analysis methods. Some new techniques for node detection, such as the Sentimag[®] technique (superparamagnetic iron oxide particles detected by a magneto-metric probe) and some new techniques for node analysis, such as the one-step nucleic acid amplification (OSNA), are accurately discussed. Finally, this book provides information also on preoperative lymph node diagnostics and sentinel lymph node biopsy perioperative complications in different nodal districts. In particular, the complications of sentinel node biopsy and for sentinel node dissection are accurately discussed with a particular focus on breast cancer, melanoma and gynecological cancers.

HB 9781536145571 £219.99 January 2019 Nova Science Publishers 327 pages

**On Display with
Wisepress**



Research on New Generation Tumor Markers

Edited by Yildiz Dincer


Many cancers are associated with the abnormal production of some molecules which can be measured in plasma/urine or can be detected on the surface of resected tumor tissue. These molecules are known as tumor markers. The potential uses of tumor markers are screening in the general population, differential diagnoses of symptomatic patients, clinical staging of cancer, estimating tumor volume, indicating prognosis, monitoring treatment and detecting recurrences. In order to obtain maximum clinical benefit, a tumor marker should have some characteristics. A tumor marker should be tissue-specific. The plasma level of the tumor marker should be in proportion to the size and activity of the tumor. A tumor marker should be present in plasma at a detectable level, even though tumor size is very small. A tumor marker should reflect the altered tumor characteristic as a response to therapy.

**On Display with
Wisepress**

Unfortunately, currently used tumor markers do not meet all of these criteria. A majority of them are present in normal, benign and tumor tissues, and unfortunately, they are not specific enough to be used for cancer screening in the general population. In addition, conventional tumor markers are poor in reflecting altered tumor behavior in response to anticancer therapy. They are of most value during follow-up appointments. Recent developments in molecular biology have led to the identification of numerous new tumor biomarkers. Firstly, the detection of DNA and RNA freely circulating in blood has provided a new perspective for the early diagnosis of cancer, patient follow-up, and assessment of therapy efficacy. Circulating free nucleic acids can originate from both malignant and non-malignant tissues. Discrimination of tumor cells is based on the presence of tumor-specific genetic and epigenetic alterations. This circulating nucleic acid-based approach is termed a “liquid biopsy.” Due to its non-invasive and repeatable features, liquid biopsy is a promising tool for cancer patients. It is particularly helpful in cancers where solid tissue biopsies are not feasible, and in the metastatic patients when multiple distinct tumor masses are simultaneously present.

As another advantage, liquid biopsy shows the current tumor dynamics during anticancer therapy and drug sensitivities that conventional examinations fail to reflect. Secondly, self-renewable stem cells have the potential to cause cancer. If stem cells are genetically or epigenetically changed, their differentiation potential becomes impaired and their proliferative capacity becomes uncontrolled. Current anticancer therapies mostly fail to eradicate cancer stem cells and instead favor expansion of the cancer stem cell pool and/or select for resistant stem cells. Thirdly, microRNAs, non-coding RNAs and transfer RNA fragments found in the bloodstream are candidate markers for the diagnosis and prognosis of different types of cancer. This book provides an overview of these new molecular tumor markers.

HB 9781536143676 £219.99 January 2019 Nova Science Publishers 339 pages




Endometrial Cancer

Risk Factors, Management and Prognosis

Edited by Simone Ferrero

Endometrial cancer is the most common gynecological cancer and the sixth cause of cancer in developed countries. The findings that EC is a heterogeneous group of tumors with distinct risk factors and histopathological features, together with our improved understanding of its molecular mechanism has paved the way to the investigation of new surgical and medical therapies. The aim of this book is to give a complete overview on risk factors, pre-operative methods and management of endometrial cancer. The authors hope that this book will be a useful tool for any health provider involved in gynecological cancer care.

HB 9781536138870 £185.99 July 2018 Nova Science Publishers 282 pages



**On Display with
Wisepress**

Pancreatic Cancer


Edited by Jana Katuchova

Pancreatic cancer is a very aggressive carcinoma with a poor prognosis. From all options currently available for pancreatic cancer patients, surgical resection offers the only potential for a cure.

The high mortality rate of pancreatic cancer is related to the advanced stage of disease at the time of diagnosis. However, it is extraordinarily difficult to make an early diagnosis of pancreatic adenocarcinoma based on clinical signs and symptoms only. Due to the nonspecific characteristics of the early symptoms and their insidious nature, pancreatic cancer is often mistaken for other diseases. Moreover, the pancreas is a relatively inaccessible organ for physical examination.

This book reviews important literature about pancreatic cancer. Chapter One of this book describes the etiology and pathology of pancreatic cancer. Chapter Two presents up-to-date possibilities in the diagnosis of pancreatic cancer. Chapter Three describes the surgical treatment of pancreatic cancer and postoperative surgical complications in detail. This chapter describes the standard and extended lymphadenectomy performed during radical pancreatic resection for pancreatic cancer. Chapter Four describes borderline pancreatic cancer and brings new knowledge concerning vascular reconstruction during radical surgical resection. Chapter Five discusses systemic therapy for patients with pancreatic cancer.

PB 9781536139822 £90.99 October 2018 Nova Science Publishers 153 pages



Laryngeal Cancer

Risk Factors, Symptoms and Treatment

Edited by Andrea De Vito, Sheng-Po Hao, Claudio Vicini

Laryngeal cancer is one of the most common cancers of the head and neck. The best diagnostic approach is provided by performing a full endoscopic evaluation, appropriate imaging and biopsy. Therapy can thereafter be tailored to pathology, stage of disease, and then individualized.


The multidisciplinary tumor board represents an essential requirement in oncologic diagnosis and treatment, often introducing clinical challenges which force us to overcome our personal opinion in solving a case in a specific manner.

This book represents a collection of our retrospective analysis of the local weekly tumor board which includes the otorhinolaryngologist, oncologist, radiotherapist, pathologist, radiologist and speech pathologist. We have also included reviews from national and international opinion leaders in the field of laryngeal cancer.

The book is organized into three sections: basic science, diagnostic work-up and treatment, with the aim of providing a concise, up-to-date, and appropriate overview of the anatomy, risk factors, conventional and newest diagnostic management, open partial laryngectomies, laser CO2 transoral laryngeal microsurgery, and conventional and robotic total laryngectomy.

The authors hope to procure a practical guideline for medical students, general practitioners, ENT specialists and, moreover, medical specialists whose roles are to provide the best up-to-date diagnostic and therapeutic management to patients with laryngeal cancer.

HB 9781536134506 £152.99 April 2018 Nova Science Publishers 148 pages



Burkitt Lymphoma

Updates in Etiology, Symptoms, Molecular Genetics and Treatment Options


Edited by Ling Zhang, Lubomir Sokol

Burkitt lymphoma (BL) is a lymphoid neoplasm originating from a mature, follicular center B-cell that is phenotypically positive for CD10, BCL-6, LOM2, and HGAL, with a hallmark genetic translocation involving the MYC gene (at 8q24) and its partner – either immunoglobulin heavy chain (14q) or light chain (kappa at 2q and lambda at 22q) – and a very aggressive clinical nature. BL can be divided into three clinical subcategories: Endemic, sporadic and HIV/AIDS/immunodeficiency with prevalence in children, adolescents and young adults. Clinical manifestations could slightly be variable upon its clinical subcategories; however, they share certain similar features, e.g., fast growing mass, frequent extranodal presentation, are associated with EBV infection, and sensitive to tumor reduction therapy with a high risk of tumor lysis syndrome and uric acid nephropathy. It is important to differentiate BL from other aggressive types of B-cell lymphomas as with intensive, short-term chemotherapy, e.g., hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and cytarabine).

Additionally, CNS prophylaxis BL showed a much better clinical response. Nearly all types of BL lack or dimly express BCL-2, differentiating it from other mimickers. A diagnostic challenging variant of BL – an MYC-negative harboring 11q abnormalities, namely “Burkitt-like lymphoma with an 11q aberration” – has been recently proposed. Novel next generation sequencing and gene expression profiling has brought about new insights into BL. TCF3(E2A), a transcription factor involving the regulation of lymphoid cell survival and proliferation, its negative regulator known as ID3, and the downstream gene CCND3 were also frequently mutated in cases of BL. The characterization of molecular biology and the genetic profile of BL leads to the future of personalized medicine and targeted therapy. This book focuses on the epidemiology, etiology, clinical presentations/staging, differential diagnoses, MYC-driven pathogenesis and therapeutic options concerning BL. These updates in BL and associated EBV- or MYC-positive diseases will benefit trainees, physicians and basic scientists who engage in the diagnosis, treatment, and novel drug development for this disease.

HB 9781536141641 £152.99 October 2018 Nova Science Publishers 171 pages

Horizons in Cancer Research Series



Horizons in Cancer Research

Edited by Hiroto S. Watanabe

Horizons in Cancer Research. Volume 69 opens with a discussion on hypothetical mechanisms of the induction of NKreg cells in cancer and possible approaches to their abrogation, suggesting that for profound understanding of the problem of NKregs in the context of future target cancer immunotherapy, extensive clinical observations of NKreg cells should be carried out. Afterwards, the authors focus on the cell surface molecules in adult T-cell leukemia/lymphoma (ATL) cells, the function of matricellular proteins, particularly OPN, and their potential as targets for ATL immunotherapy. Later, the book demonstrates dual distinct functional roles of widespread cancerous immunoglobulins among cancer cells for the potential applications of RP215 in therapeutic treatments of many human cancers. RP215-linked chimeric antigen receptor (CAR)-T cell therapy technology has been applied in anti-cancer treatments through a series of CAR construction and validations by cytotoxic cell killing and cytokine activity release assays. Next, the authors present a new approach to describing, analyzing and understanding the process of dying in cancer patients based on the assumption that there are four tracks along which dying proceeds: the track focused on the medical-diagnostic aspects of the disease, the track referring to the physical aspects of the disease, the track defined by the psychological aspects of the disease and the track describing the coping- determined aspects of dying. In a separate study, examples of cases using a flexible, inflatable multi-channel applicator for the treatment of primary and recurrent gynecologic cancer, as well as treatment with Syed interstitial brachytherapy are presented. The examples are intended to emphasize the different characteristics of patient's anatomy and tumors that guide the selection of a particular applicator and brachytherapy technique. Afterwards, the role of emodin in cancer prevention is discussed. Emodin possesses a broad spectrum of pharmacological, anticancer, anti-inflammatory, antioxidant and antimicrobial activities.


Volume 69 HB 9781536132960 £238.99 April 2018 Nova Science Publishers 215 pages

Volume 70 HB 9781536141863 £238.99 October 2018 Nova Science Publishers 211 pages

Volume 71 HB 9781536152074 £238.99 April 2019 Nova Science Publishers 205 pages

Volume 72 HB 9781536158120 £238.99 July 2019 Nova Science Publishers 251 pages

Medicine & Biology Research Developments Series



Meningiomas in Children and Adults


A Reference Textbook

Edited by Ali G. Saad

This book is an in depth review of the most recent advances in the histopathology, molecular studies, radiology, and management of meningioma. This book contains a separate chapter about pediatric meningioma, with an emphasis on their distinctive features compared to their adult counterparts. This book also addresses several aspects of meningiomas including extradural meningiomas and embolized meningiomas. These aspects have been traditionally poorly explored in the literature. We believe that this book will be positively received by pathologists, neuro-radiologists, and neuro-oncologists alike.

HB 9781536130430 £219.99 March 2018 Nova Science Publishers 203 pages

Nutrition & Diet Research Progress



Plant Flavonoids Affect Cancer Chemotherapeutic Efficacy A Handbook for Doctors and Patients


Katrin Sak, PhD

Despite intensive work on molecular carcinogenic mechanisms and novel drug development, cancer has still remained an incurable disease. With the hope to gain therapeutic advantage or miracle cure, more than 50% of cancer patients consume various kinds of herbal supplements when undergoing chemotherapeutic treatment with antineoplastic agents.

However, numerous preclinical studies on combined treatment of various cancer cells with natural dietary flavonoids and chemotherapeutic drugs have revealed both desired (additive to synergistic) as well as undesired (antagonistic) interactions, meaning that coadministration of flavonoids and chemotherapeutic drugs can lead to both augmentation as well as abolishment of therapeutic efficacy. This book is the first one to systematically compile currently available information about the modulation of chemotherapeutic efficacy by flavonoids, hopefully being an assistant for cancer patients to make conscious choices in selecting proper plant products during chemotherapeutic treatment.

HB 9781536159578 £219.99 July 2019 Nova Science Publishers 428 pages

Radiation Oncology: Clinical, Translational & Laboratory Research Series



Recent Advancements and Applications of Dosimetry

Edited by Maria F. Chan

Features

- Provides unique dosimetry for high intensity MR-guided ultrasound treatment, gold nanoparticle-enhanced radiotherapy, photodynamic therapy, thermal imaging in Brachytherapy, MR-guided radiotherapy, proton beam treatment, and high-definition end-to-end patient-specific dose verification
- Offers clinical applications for all varieties of modern radiation detectors, and evolving dosimetry techniques including innovative calorimetry, TLD, Oone-scan film dosimetry, transmission detectors, real-time EPID dosimetry, best feasible DVH planning, 3D printing, 5D planning and delivery, as well as machine learning

Summary

This book provides a comprehensive collection of the newly emerging treatment modalities, covering high intensity ultrasound treatment, photodynamic therapy, MR-guided treatment machines, nanoparticle-enhanced radiotherapy, and proton beam therapy. The invited expert authors cover a wide range of the latest advancements and developments in dosimetry techniques as well as their clinical implications, including calorimetry, radiochromic film, transmission detectors, real-time portal dosimetry, TLD, thermal imaging dosimetry, 3D dosimetry, best feasible DVH planning, 5D planning and delivery, 3D printing, as well as machine learning in medical dosimetry. This book will bring the reader up-to-date with the state of the art in radiation dosimetry and best clinical practices using such advanced detectors.

HB 9781536137590 £219.99 July 2018 Nova Science Publishers 401 pages



Gazelle Book Services Ltd.

White Cross Mills
Hightown
Lancaster
Lancashire
LA1 4XS

Telephone: +44 (0) 1524 528500

Fax: +44 (0) 1524 528510

Email: sales@gazellebookservices.co.uk

Gazelle Book Services Order Form - (Books listed alphabetically by title)

Title	FORMAT	ISBN	RRP (£)	Qty	Total
Acute Myeloid Leukaemia (AML)	PB	9781536143454	£ 78.99		
Adjuvant Chemotherapy	HB	9781536139334	£ 219.99		
Basal Cell Carcinoma	HB	9781536153392	£ 219.99		
Bladder Cancer	HB	9781536133547	£ 185.99		
Burkitt Lymphoma	HB	9781536141641	£ 152.99		
Clinical Oncoproteomics	HB	9781536144772	£ 219.99		
Encyclopedia of Breast Cancer - 3 Volume Set	HB	9781536156973	£ 471.99		
Endometrial Cancer	HB	9781536138870	£ 185.99		
Frontiers in Leukemia Pharmacotherapy	HB	9781536149609	£ 219.99		
Horizons in Cancer Research - Volume 69	HB	9781536132960	£ 238.99		
Horizons in Cancer Research - Volume 70	HB	9781536141863	£ 238.99		
Horizons in Cancer Research - Volume 71	HB	9781536152074	£ 238.99		
Horizons in Cancer Research - Volume 72	HB	9781536158120	£ 238.99		
Laryngeal Cancer	HB	9781536134506	£ 152.99		
Meningiomas in Children and Adults	HB	9781536130430	£ 219.99		
New Developments in Oncology Research	HB	9781536153651	£ 152.99		
Pancreatic Cancer	PB	9781536139822	£ 90.99		
Plant Flavonoids Affect Cancer Chemotherapeutic Efficacy	HB	9781536159578	£ 219.99		
Quantum Biology	PB	9781536147759	£ 78.99		
Recent Advancements and Applications of Dosimetry	HB	9781536137590	£ 219.99		
Research on New Generation Tumor Markers	HB	9781536143676	£ 219.99		
The Medulloblastoma Book	HB	9781536151527	£ 219.99		
The Sentinel Lymph Node	HB	9781536145571	£ 219.99		
The Story of Hydra	HB	9781536153736	£ 219.99		



New Titles: Cancer Research
Titles published by Nova Science

CANCER ETIOLOGY, DIAGNOSIS AND TREATMENTS

New
Developments
in Oncology
Research



Marcos T. Blair
Editor



National Cancer Research Institute Cancer Conference 2019
3-5th November 2019
Scottish Event Campus, Glasgow

Cancer Etiology,
Diagnosis &
Treatments

Horizons In Cancer
Research

Medicine & Biology
Research
Developments

Nutrition & Diet
Research Progress

Radiation
Oncology: Clinical,
Translational &
Laboratory
Research

Nova
Medicine &
Health